University Hospitals Coventry and Warwickshire NHS Trust
Coventry, West Midlands, CV2 2DX, United Kingdom
NCT Number: NCT03341676
When the brain detects a drop in oxygen levels in the blood (hypoxia) there is a compensatory increase in blood flow. Acute mountain sickness (AMS) is a cluster of symptoms which commonly occur in those ascending to high altitude and experiencing hypoxia due to increased blood flow and then swelling in the brain. Symptoms include headache, nausea, insomnia and fatigue. The exact mechanisms by which AMS develops remains poorly understood. Dexamethasone has been shown to reduce the risk of developing significant brain swelling in other settings. Therefore we hypothesise that administering low dose Dexamethasone could protect against hypoxia induced cerebral and spinal oedema.
Looking for future studies?
Notify Me20 year–50 year
All sexes
Interventional
Phase 1
Coventry, West Midlands, CV2 2DX, United Kingdom
The exact mechanisms by which AMS develops remains poorly understood. Interestingly, brain and spinal cord swelling due to low oxygen levels can also occur in the period following surgery to treat thoracic and abdominal aortic aneurysms, dangerous swellings of the major blood vessel in the body. Therefore, if we find a therapeutic benefit of receiving a dose of Dexamethasone in a controlled, reversible setting of hypoxia, it is possible that this could be useful in the treatment of post-operative hypoxia as well.
Work with MRI imaging has demonstrated reduced measures of water movement in patients suffering from cerebral or spinal ischaemia, due to swelling. Specific water channels in brain cells (astrocytes) are involved in the movement of water, and Dexamethasone has been shown to reduce expression of these channels in animal models. Dexamethasone already plays a role in lowering pressure in the brain in the setting of brain tumours. Although high doses are typically used in this setting, there is evidence that lower doses may be equally effective, especially in patients with less severe swelling.
Subjects will be consented and randomised in the weeks before the actual study.
Before entering the tent, the following data will be collected:
Non-invasive monitoring will continue every 2 hours at the start of the study and around the time of administration of the study drug. They will continue at less frequent intervals throughout the study period. This includes ECG trace and an AMS self-assessment questionnaire.
Venous sampling will be performed on 5 occasions throughout the study. Finger prick sampling will be done at the same time points
Each subject will have 5 MRI scans during the course of the study.
Subjects will be begin hypoxication 1 hour after entering the tent. They will be returned to normal oxygen levels after 24 hours.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Dexamethasone 3.3 mg/mL solution for injection
Sodium Chloride 0.9% w/v solution for injection
Time frame: 0 hour and 8, 11, 22 and 26 hours post hypoxic insult
Differences in oedematous changes in the brain and spinal cord as measured by changes in brain and spinal cord MRI imaging
Time frame: 0 hour and 8, 11, 22 and 26 hours post hypoxic insult
To assess the role of primary blood brain barrier breakdown in hypoxic cytotoxic oedema as measured by variation in serum markers
Time frame: 0 hour and 8, 11, 22 and 26 hours post hypoxic insult
Change in glial specific (GFAP) and non-glial specific (purines) serum biomarkers from baseline and at 8, 11, 22 and 26 hours post hypoxic insult
Time frame: 0 hour and 8, 11, 22 and 26 hours post hypoxic insult
To develop a hypoxic spinal cord model for use in future research looking into complex vascular surgery.
University Hospitals Coventry and Warwickshire NHS Trust
Other
Acronym: D4H
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06039475
Acute Mountain Sickness, Altitude Sickness
Jomsom, Gandaki, Nepal
View Trial DetailsNCT06894550
Altitude, Altitude Sickness
Bern, Canton of Bern, Switzerland
View Trial DetailsNCT07608887
Altitude Sickness, Altitude Training Adaptation
Macao, China
View Trial DetailsNCT06498505
Altitude Sickness, High Altitude
Bishkek, Kyrgyzstan
View Trial Details